Bay Area-based Dren Bio, Inc. and Novartis will collaborate on discovering and developing new bispecific antibodies for cancer using Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform. Read more below: https://lnkd.in/ehpVTbMQ #partnership #bionews #pharmanews
About us
Mantell Associates is a multi-discipline headhunting firm focused on providing both permanent and contract recruitment services globally, to the Biotech, Pharmaceutical, CDMO, CRO, Diagnostics, Animal Health, Consulting, Medical Device and MedTech sectors. With success ranging across C-Suite, Commercial, Technical Operations, Scientific, Clinical, Quality and Regulatory, we pride ourselves on our ability to bring the top talent to our clients, and the best opportunities to the top talent. Our services span across our Partnership Service, Contingency, Project Management and Contract models, meaning that we can cater to our client’s every requirement.
- Website
-
www.mantellassociates.com
External link for Mantell Associates
- Industry
- Executive Search Services
- Company size
- 51-200 employees
- Headquarters
- City of London, England
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Contract Development Manufacturing Organisations, Contract Manufacturing Organisations, Preclinical, Active Pharmaceutical Ingredients, Cell & Gene Therapy, Finished Dosage Forms, Biologics, Toxicology, Pharmacology, Oncology, CDMO, CMO, Biomarkers, Vaccines, Contract Research Organisation, Clinical Trial Supplies, Bioanalytics, Bioanalysis, Fine Chemicals, and Highly Potent Active Pharmaceutical Ingredients
Locations
-
Primary
150 Minories
City of London, England EC3N 1LS, GB
-
2 S Biscayne Blvd
Miami, Florida 33131, US
-
Rigistrasse 3
Zug, 6300, CH
Employees at Mantell Associates
Updates
-
The cell and gene therapy industry is experiencing rapid growth and evolution, presenting both exciting opportunities and unique challenges for researchers and logistics providers alike. At the forefront of this revolution is Emilio Frattaruolo, CPPL, Vice President of Cell and Gene Therapies at CSafe. In a recent interview, Frattaruolo shared insights into the changing landscape of cell and gene therapies and the critical role of cold chain logistics in their successful delivery. Read more below: https://lnkd.in/gZt2xx2E #cellandgene #celltherapy #genetherapy
Cell and gene therapies: Navigating the cold chain revolution
fiercebiotech.com
-
Agilent Technologies Inc. has signed a definitive agreement to acquire BIOVECTRA, a specialized CDMO, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. Read more below: https://lnkd.in/e9DbS5uk #cdmo #acquisition #therapeutics
Agilent Technologies Agrees to Acquire BIOVECTRA
contractpharma.com
-
What an afternoon for our monthly Lunch Club in Miami, hosted by MD James Aiton! Our US team enjoyed lunch and drinks at Watr at the 1 Rooftop in Miami Beach. Congratulations to Robin Mantell, Greg Wade and Simone Torres - well deserved! #recruitmentmiami #recruitmentincentives #lifesciencerecruitment
-
-
Low double-digit growth in quarterly medical device sales has pushed Abbott to nudge up its earnings projections for the year. Read more below: https://lnkd.in/eV2-k9tS #medicaldevices #sales #meddev
Growing medical device sales push Abbott to raise full-year forecast
fiercebiotech.com
-
Last Friday our June top performers celebrated with our monthly Lunch Club in London, hosted by Director Siobhan McLoughlin! It was a great afternoon, starting with drinks in the sunshine at Wagtail Rooftop Bar and Restaurant, followed by an amazing lunch at The Maine in Mayfair! Huge congrats to everyone who qualified, well deserved - Thomas White, Sophie Packer, Ewan Rennison, Zac Cisotti, Jay Lefley, Conor O'Shea, Huseyin Pulat and Emer Brady. Our Lunch Club is designed to celebrate success and spend time out of the office as a team - well done everyone, we're already looking forward to the next one! #recruitmentlondon #recruitmentincentives #incentives
-
Eli Lilly and Company’s $3.2 billion Morphic Therapeutic buyout is a story of two companies gradually closing the gap between their positions before tying the knot. Read more below: https://lnkd.in/gkbmRsQn #investment #pharmanews #merger
Morphic kept it simple in M&A maneuvers, staying focused on Lilly to reel in $3.2B buyout
fiercebiotech.com
-
Full-Life Technologies, a global radiotherapeutics company, has entered into a license agreement with SK Biopharmaceuticals, a global biotech company, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life's FL-091 radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers. Read more below: https://lnkd.in/e4NYmYJM #smallmolecule #cancertreatment #radiationtherapy
Full-Life Technologies, SK Biopharma Enter $571.5M License Agreement for FL-091
contractpharma.com
-
New opportunity! Senior Director of Business Development - CRO - Europe. Mantell Associates has partnered with a global CRO to aid their search for a Senior Director of Business Development to own their European Sales division. With a global reach and a full end-to-end service offering from Research through to Manufacturing this company is looking to continue their European Success through a hands on, "hunter-mindset" focused Business Developer. Apply for this role online - https://lnkd.in/eYAjRaNr - or contact Sophie Packer. #crojobs #businessdevelopmentjobs #bdjobs
-
-
Fernand Desjarlais discusses the impact of the US Biosecure Act on the Life Science market. Approved by the US House Committee for Oversight and Accountability, the Act seeks to enhance national security by restricting US federal funding to entities engaged with certain foreign biotechnology companies. Read more below: https://lnkd.in/etXr_J25 #lifesciences #biosecureact #chinesebiotech
The Impact of the BIOSECURE Act on US Life Sciences
mantellassociates.com